Document Detail

DPP4 inhibitors for diabetes--what next?
MedLine Citation:
PMID:  18755155     Owner:  NLM     Status:  MEDLINE    
With vildagliptin and sitagliptin on the market for the treatment of type 2 diabetes, dipeptidyl peptidase 4 (DPP4, EC research has entered a new era. Scientists aim to uncover the broader pharmacological profile of DPP4 inhibitors and search for therapeutic opportunities outside diabetes. During the pre-clinical and clinical evaluation of vildagliptin and sitagliptin, there has been a growing awareness of the presence of other DPP4-like peptidases in various cells and tissues. This fuelled the development of more inhibitors with defined selectivity for DPP2, 8 and 9 that were used to investigate the expression, distribution and regulation of these peptidases. In turn, these studies increased the insights in the role of DPP4 in the body's response to various insults.
Anne-Marie Lambeir; Simon Scharpé; Ingrid De Meester
Related Documents :
11832995 - Resistance of succinic acid dimethyl ester insulinotropic action to exendin (9-39) amide.
2238765 - Carbachol priming increases glucose- and glucagon-like peptide-1 (7-36)amide-, but not ...
8473405 - Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypep...
8819215 - Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polyp...
7081085 - Effect of vitamin e deficiency on rabbit intramuscular collagen.
23911175 - A composite model of glucagon-glucose dynamics for in silico testing of bihormonal gluc...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2008-07-31
Journal Detail:
Title:  Biochemical pharmacology     Volume:  76     ISSN:  1873-2968     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-01     Completed Date:  2008-12-24     Revised Date:  2009-05-21    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1637-43     Citation Subset:  IM    
Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adamantane / analogs & derivatives
Diabetes Mellitus / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / metabolism*,  therapeutic use
Neoplasms / drug therapy
Reg. No./Substance:
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Nitriles; 0/Pyrazines; 0/Pyrrolidines; 0/Triazoles; 0/sitagliptin; 0/vildagliptin; 281-23-2/Adamantane

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  PICK1 binds to calcineurin B and modulates the NFAT activity in PC12 cells.
Next Document:  Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in ...